

MARKET REPORT



UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

<https://www.bioportfolio.co.uk/product/215213>
bioportfolio97@gmail.com to order

Jun 28,2018: New UCB Research Showcases Value of CIMZIA (certolizumab pegol) in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient Populations

Jun 19,2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA]

Jun 15,2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey

Jun 01,2018: UCB proud to collect Wallonia Export Award

May 22,2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Additional Details

Publisher : Global Data
Reference : GDPH33857FSA
Number of Pages : 56
Report Format : PDF
Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

- Table of Contents Table of Contents 3List of Tables 5List of Figures 5Section 1 - About the Company 6UCB SA - Key Facts 6UCB SA - Key Employees 7UCB SA - Key Employee Biographies 8UCB SA - Major Products and Services 9UCB SA - History 10UCB SA - Company Statement 17UCB SA - Locations And Subsidiaries 19Head Office 19Other Locations & Subsidiaries 19Joint Venture 22Section 2 - Company Analysis 23Company Overview 23UCB SA - Business Description 24UCB SA - Corporate Strategy 25UCB SA - SWOT Analysis 26SWOT Analysis - Overview 26UCB SA - Strengths 26UCB SA - Weaknesses 27UCB SA - Opportunities 28UCB SA - Threats 29UCB SA - Key Competitors 30Section 3 - Company Financial Ratios 31Financial Ratios - Capital Market Ratios 31Financial Ratios - Annual Ratios 32Performance Chart 35Financial Performance 35Financial Ratios - Interim Ratios 36Financial Ratios - Ratio Charts 37Section 4 - Company's Lifesciences Financial Deals and Alliances 38UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39UCB SA, Recent Deals Summary 40Section 5 - Company's Recent Developments 41Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA] 41Jun 15, 2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey 42Jun 01, 2018: UCB proud to collect Wallonia Export Award 43May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 44May 07, 2018: Partnership with Science 37: helping UCB to improve patient experience 45May 03, 2018: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home 46Apr 23, 2018: Sharing research & supporting development of future neurology leaders at AAN 2018 47Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 49Mar 21, 2018: GoBoldy: R&D Is An Investment In New Era Of Medicine 50Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 51Section 6 - Appendix 52Methodology 52Ratio Definitions 52About GlobalData 56Contact Us 56Disclaimer 56

List Of Tables in UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

List of Tables

UCB SA, Key Facts 6

UCB SA, Key Employees 7

UCB SA, Key Employee Biographies 8

UCB SA, Major Products and Services 9

UCB SA, History 10

UCB SA, Subsidiaries 19

UCB SA, Joint Venture 22

UCB SA, Key Competitors 30

UCB SA, Ratios based on current share price 31

UCB SA, Annual Ratios 32

UCB SA, Annual Ratios (Cont...1) 33

UCB SA, Annual Ratios (Cont...2) 34

UCB SA, Interim Ratios 36

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39

UCB SA, Recent Deals Summary 40

Currency Codes 52

Capital Market Ratios 52

Equity Ratios 53

Profitability Ratios 53

Cost Ratios 54

Liquidity Ratios 54

Leverage Ratios 55

Efficiency Ratios 55

List Of Figures, Charts and Diagrams in UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

List of Figures

UCB SA, Performance Chart (2013 - 2017) 35

UCB SA, Ratio Charts 37

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 39

How to Buy...

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/215213>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$106** | Single User Price
- \$213** | Site License Price
- \$319** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.